Udayan Guha

Chief Tech/Sci/R&D Officer at NEXTCURE, INC.

Net worth: - $ as of 30/06/2026

54 year

Consumer Services

Health Technology

Profile

Udayan Guha currently works at NextCure, Inc., as Chief Medical Officer from 2025.
Dr. Guha also formerly worked at TCR² Therapeutics, Inc., as Vice President & Head-Clinical Development from 2022 to 2023.
Dr. Guha received his graduate degree from All India Institute of Medical Sciences and doctorate degree from Albert Einstein College of Medicine, Inc.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
NEXTCURE, INC. -.--%	22/04/2026	0 ( -.--% )	- $	30/06/2026

Udayan Guha active positions

Companies	Position	Start
NEXTCURE, INC.	Chief Tech/Sci/R&D Officer	01/03/2023

All active positions of Udayan Guha

Former positions of Udayan Guha

Companies	Position	End
TCR2 THERAPEUTICS INC.	Corporate Officer/Principal	01/04/2023

See the detail of Udayan Guha's experience

Training of Udayan Guha

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Udayan Guha's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
All India Institute of Medical Sciences All India Institute of Medical Sciences Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Albert Einstein College of Medicine, Inc. Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
NextCure, Inc. NextCure, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases	Health Technology
TCR2 Therapeutics, Inc. TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy	Health Technology